248 related articles for article (PubMed ID: 18491250)
1. New approaches to the therapy of various tumors based on peptide analogues.
Schally AV
Horm Metab Res; 2008 May; 40(5):315-22. PubMed ID: 18491250
[TBL] [Abstract][Full Text] [Related]
2. Hypothalamic hormones and cancer.
Schally AV; Comaru-Schally AM; Nagy A; Kovacs M; Szepeshazi K; Plonowski A; Varga JL; Halmos G
Front Neuroendocrinol; 2001 Oct; 22(4):248-91. PubMed ID: 11587553
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy targeted to cancers through tumoral hormone receptors.
Schally AV; Nagy A
Trends Endocrinol Metab; 2004 Sep; 15(7):300-10. PubMed ID: 15350601
[TBL] [Abstract][Full Text] [Related]
4. [New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin].
Schally AV
An R Acad Nac Med (Madr); 2004; 121(3):493-500. PubMed ID: 15751842
[TBL] [Abstract][Full Text] [Related]
5. Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms.
Schally AV; Redding TW; Comaru-Schally AM
Cancer Treat Rep; 1984 Jan; 68(1):281-9. PubMed ID: 6362868
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
7. New treatment approaches for prostate cancer based on peptide analogues.
Stangelberger A; Schally AV; Djavan B
Eur Urol; 2008 May; 53(5):890-900. PubMed ID: 18201818
[TBL] [Abstract][Full Text] [Related]
8. Luteinizing hormone releasing hormone analogues for contraception.
Nillius SJ
Clin Obstet Gynaecol; 1984 Dec; 11(3):551-72. PubMed ID: 6391776
[TBL] [Abstract][Full Text] [Related]
9. [History of clinical studies on hypothalamic hormone analogs in Mexico].
Schally AV; González Bárcena D
Gac Med Mex; 2006; 142(4):315-25. PubMed ID: 17022307
[TBL] [Abstract][Full Text] [Related]
10. Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors.
Schally AV; Engel JB; Emons G; Block NL; Pinski J
Curr Drug Deliv; 2011 Jan; 8(1):11-25. PubMed ID: 21034424
[TBL] [Abstract][Full Text] [Related]
11. Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma.
Srkalovic G; Wittliff JL; Schally AV
Cancer Res; 1990 Mar; 50(6):1841-6. PubMed ID: 2155060
[TBL] [Abstract][Full Text] [Related]
12. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer.
Schally AV; Varga JL; Engel JB
Nat Clin Pract Endocrinol Metab; 2008 Jan; 4(1):33-43. PubMed ID: 18084344
[TBL] [Abstract][Full Text] [Related]
13. Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207.
Kahán Z; Nagy A; Schally AV; Halmos G; Arencibia JM; Groot K
Cancer; 1999 Jun; 85(12):2608-15. PubMed ID: 10375109
[TBL] [Abstract][Full Text] [Related]
14. [Gonadotropin-releasing hormone analogues in the treatment of metastatic breast carcinoma].
Nesković-Konstantinović Z; Radulović S; Vuletić L
Srp Arh Celok Lek; 1993; 121(1-2):33-5. PubMed ID: 8202820
[TBL] [Abstract][Full Text] [Related]
15. Gn-RH agonists in the treatment of prostatic carcinoma.
Vacher P
Biomed Pharmacother; 1995; 49(7-8):325-31. PubMed ID: 8562857
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors.
Kidd M; Schally AV; Pfragner R; Malfertheiner MV; Modlin IM
Cancer; 2008 Mar; 112(6):1404-14. PubMed ID: 18224665
[TBL] [Abstract][Full Text] [Related]
17. LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy.
Szepeshazi K; Schally AV; Halmos G
Int J Oncol; 2007 Jun; 30(6):1485-92. PubMed ID: 17487370
[TBL] [Abstract][Full Text] [Related]
18. Regulation of targeted chemotherapy with cytotoxic lutenizing hormone-releasing hormone analogue by epidermal growth factor.
Krebs LJ; Wang X; Pudavar HE; Bergey EJ; Schally AV; Nagy A; Prasad PN; Liebow C
Cancer Res; 2000 Aug; 60(15):4194-9. PubMed ID: 10945629
[TBL] [Abstract][Full Text] [Related]
19. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
Chatzistamou L; Schally AV; Nagy A; Armatis P; Szepeshazi K; Halmos G
Clin Cancer Res; 2000 Oct; 6(10):4158-65. PubMed ID: 11051271
[TBL] [Abstract][Full Text] [Related]
20. Hypothalamic hormones: from neuroendocrinology to cancer therapy.
Schally AV
Anticancer Drugs; 1994 Apr; 5(2):115-30. PubMed ID: 8049494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
